{"id":9648,"date":"2026-10-29T16:53:27","date_gmt":"2026-10-29T11:23:27","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/lauruslabs-share-price-today-2026-10-29\/"},"modified":"2026-10-29T16:53:29","modified_gmt":"2026-10-29T11:23:29","slug":"lauruslabs-share-price-today-2026-10-29","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/lauruslabs-share-price-today-2026-10-29\/","title":{"rendered":"Laurus Labs Share Price Today: Why LAURUSLABS Is Rising 2.85% | 29 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: LAURUSLABS<\/strong> \u00b7 29 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b92,244.00<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+2.85%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b92,244.00 \/ \u20b92,166.50<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b92,181.90<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>28.68 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>29 October 2026 \u00b7 03:25 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Laurus Labs Limited shares advanced 2.85% today, trading near the upper end of the session. The stock opened at \u20b92,185.10 and touched a day&#x27;s high of \u20b92,244.00, which also marks a new 52-week high, against a low of \u20b92,166.50.<\/li>\n<li>Trading volume was 1.77 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Laurus Labs share price rising on 29 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Laurus Labs Limited shares advanced 2.85% today, trading near the upper end of the session. The stock opened at \u20b92,185.10 and touched a day&#x27;s high of \u20b92,244.00, which also marks a new 52-week high, against a low of \u20b92,166.50.<\/p>\n<p class=\"wt-copy\">The broader market and sector backdrop remained supportive during the session. The benchmark Nifty rose 1.05%, while the Nifty Pharma sector index posted a 0.64% gain, indicating positive sentiment across pharmaceutical equities. Laurus Labs&#x27; intraday momentum outperformed both the wider market and its sector peers, supported by strong trailing returns of 12.06% over the past 5 trading days and 13.39% over the past 20 trading days.<\/p>\n<p class=\"wt-copy\">The upward price action coincided with the release of strong financial results for the quarter and half-year ended September 30, 2026, alongside corporate announcements detailing strategic acquisitions. Laurus Labs reported a 33% year-on-year increase in revenue to \u20b92,206 crore and a 126% jump in net profit to \u20b9441 crore for the quarter, while also announcing definitive agreements to acquire majority stakes in Galenvs Sciences and SI &amp; C Resins to strengthen its CDMO and peptide capabilities.<\/p>\n<p class=\"wt-copy\">28.68 lakh shares traded by 29 October 2026 \u00b7 03:25 PM IST. This compares with a 20-day average daily volume of 16.23 lakh shares (1.77 times). The five-day average daily volume was 21.22 lakh shares. Separately, the NSE report for 28 October 2026 showed 9.21 lakh shares delivered, representing 41.85% of that day\u2019s traded volume. The same report recorded 66,516 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Strong quarterly financial results and strategic CDMO acquisitions<\/strong><\/p>\n<p class=\"wt-copy\">The stock&#x27;s 2.85% rise to a new 52-week high on elevated trading volume directly coincides with the public release of financial results showing substantial year-on-year revenue and profit growth, alongside announcements of major strategic acquisitions in the oligonucleotide and peptide spaces.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">27.47%<\/div>\n<div class=\"wt-note\">27.47% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">30.84%<\/div>\n<div class=\"wt-note\">28.00% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">42.70%<\/div>\n<div class=\"wt-note\">41.74% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742798_21102026030442_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"insider\" style=\"background:#edf5ff;border:1px solid #c9dbef;border-left:4px solid #4b7fb8;border-radius:10px\">\n<div class=\"wt-card-title\">Historical Insider Activity<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>PRATHIMA CHAVA<\/strong><span class=\"wt-note\">Insider \/ disclosed person<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Pledge<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>2.00 lakh shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>2 December 2024<\/strong><\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">Source: NSE transaction disclosures. These are dated historical transactions.<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 8.26% on 30 September 2026. This compares with 10.15% on 30 June 2026, a change of -1.89 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 38 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">MIRAE ASSET NIFTY INDIA MANUFACTURING ETF<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.17 crore shares \u00b7 4.02%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742798_21102026030442_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">BNP PARIBAS FINANCIAL MARKETS<\/div>\n<div class=\"wt-card-date\">31 August 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 62.72 lakh shares \u00b7 \u20b91,914.28<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.<\/div>\n<div class=\"wt-card-date\">31 August 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 51.34 lakh shares \u00b7 \u20b91,914.04<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">SOCIETE GENERALE<\/div>\n<div class=\"wt-card-date\">31 August 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 28.10 lakh shares \u00b7 \u20b91,903.84<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">BNP PARIBAS FINANCIAL MARKETS<\/div>\n<div class=\"wt-card-date\">31 August 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 15,399 shares \u00b7 \u20b91,860.35<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution progress and integration timelines for newly acquired Galenvs Sciences and SI &amp; C Resins<\/li>\n<li>Ramp-up and commercial utilization rates at the newly inaugurated peptide manufacturing facility in Vizag<\/li>\n<li>Delivery volume trends and cash market participation relative to the 20-day average volume of 1.77x<\/li>\n<li>Upcoming interim dividend record date scheduled for November 6, 2026<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/lauruslabs-share-price-today-2026-10-28\/\">Laurus Labs Share Price Today: Rises 10.76% in 3 Trading Sessions | 28 October 2026 \u2014 28 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/lauruslabs-share-price-today-2026-10-27\/\">Laurus Labs Share Price Today: Why LAURUSLABS Is Rising 4.04% | 27 October 2026 \u2014 27 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/lauruslabs-share-price-today-2026-10-23\/\">Laurus Labs Share Price Today: Why LAURUSLABS Is Falling 1.94% | 23 October 2026 \u2014 23 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/lauruslabs\/\">More Laurus Labs news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>How strong was Laurus Labs\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">28.68 lakh shares traded, 1.77 times the 20-day average daily volume. The price and volume data are dated 29 October 2026 \u00b7 03:25 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/lauruslabs-share-price-today-2026-10-29\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/lauruslabs-share-price-today-2026-10-29\/\"}, \"headline\": \"Laurus Labs Share Price Today: Why LAURUSLABS Is Rising 2.85% | 29 October 2026\", \"description\": \"Laurus Labs share price rose 2.85% to \u20b92,244.00 today. See why LAURUSLABS is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-29T16:53:17.265918+05:30\", \"dateModified\": \"2026-10-29T16:53:17.265918+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Laurus Labs\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"LAURUSLABS\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/lauruslabs-company-news-2026-10-29.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Investor Presentation\",\"summary\":\"Investor Presentation\",\"source\":\"NSE\",\"published\":\"29-Oct-2026 15:18:54\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/LAURUSLABS_29102026151833_InvPresentation29102026.pdf\",\"disclosure_text\":\"October 29, 2026 To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai \u2013 400 001 Code: 540222 To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai \u2013 400 051 Code: LAURUSLABS Dear Sir \/ Madam, Sub: Investors \/ Analysts Presentation Please find enclosed the presentation to the Investors \/ Analysts on the Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026, for the Investors \/ Analysts call scheduled on October 29, 2026 at 05.00 p.m. (IST), which was already intimated on October 13, 2026. The presentation is also being uploaded on the website of the Company i.e., www.lauruslabs.com. This is for your information and records. Thanking you. Yours sincerely, For Laurus Labs Limited V V Ravi Kumar Executive Director and CFO DIN: 01424180 Encl: A\/a \u00a9 2026 Laurus Labs Ltd. Q2 & H1-FY 2027 Financial Results 29\/10\/2026 20 Years logo \u00a9 2026 Laurus Labs Ltd. 29\/10\/2026Q2 & H1 - FY27 Results Presentation This presentation contains statements that constitute \u201cforward looking statements\u201d including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations. These factors include, but not limited to: 1) Change in the General market and macro-economic conditions for key global markets where we operate, 2) Governmental and regulatory trends, 3) Allocations of funds by the Governments in our key global markets, 4) Successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 5) Movements in currency exchange and interest rates, 6) Increase in the competitive pressures and Technological developments, 7) Changes in the financial conditions of third parties dealing with us, 8) Changes in laws and regulations that apply to our customers, suppliers and Pharmaceutical industry. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Laurus Labs Limited may vary materially from those described in the relevant forward-looking statements The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation as a result of new information, future events or otherwise. This presentation is strictly confidential and may not be copied or disseminated, reproduced, re-circulated, re-distributed, published or advertised in any media, website or otherwise, in whole or in part, and in any manner or for any purpose without written approval from Laurus Labs Limited. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited. This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue ofCapital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information fromthis presentation shall be governed by the laws of India and only the courts in Telangana, India, and no other courts, shall have jurisdiction over the same. Safe Harbor Statement 2 \u00a9 2026 Laurus Labs Ltd. 29\/10\/2026Q2 & H1 - FY27 Results Presentation 1 Q2 & H1 - FY 2027 Corporate Overview 2 Q2 & H1 - FY 2027 Financial Overview 3 Q2 & H1 - FY 2027 Business Review & Strategy Agenda 3 1 Corporate Overview Q2 & H1 FY 2027 4 \u00a9 2026 Laurus Labs Ltd. 29\/10\/2026Q2 & H1 - FY27 Results Presentation Executive Summary 5 \u2022 Strong H1 performance ; \u20b9 4,233 Cr Revenue with 31% growth \u2022 Sustained strong growth in CDMO revenue driven by commercial supplies and steady momentum in Affordable Medicines division \u2022 \u20b9 1,406 Cr EBITDA with margins of 33.2%, increased by 7.8% pts, contributed by higher CDMO revenue and operational leverage \u2022 Gross margins expansion of over 3.3% pts to 62.9% on healthy business segment mix \u2022 Announced investments in two technology platforms to strengthen Integrated CDMO offering; Oligonucleotides and peptide-resins \u2022 CAPEX\/Revenue reached 20%, reflecting sustained investment in expanding the manufacturing network and niche capabilities \u00a9 2026 Laurus Labs Ltd. 29\/10\/2026Q2 & H1 - FY27 Results Presentation Strengthen CDMO expertise \u2013 Proposed Acquisition Overview \u2022 Definitive agreement to acquire 60% stake in Galenvs, specialized in Oligonucleotide and Precision Magnetic Nanoparticles for purification \u2022 Expands Laurus position in fast growing Oligo market (+22-24% CAGR) with a North American development footprint \u2022 Galenvs early-stage Oligo platform + Laurus large-scale expertise in complex chemistry allows to deliver Integrated service for complex RNA\/DNA based therapies \u2022 Plans to expand scientific talent in Montreal and manufacturing infrastructure in India Expanding CDMO offering in high growth Oligonucleotide modality Galenvs capabilities Antisense, Aptamers siRNA sgRNA Advance purification incl fill finish Pilot-scale synthesis Market size ~$ 11 bn+ 2030 +22-24% CAGR \u2022 Proposed to acquire 52% stake in SI &C Resins, a peptide-resin technology focused company \u2022 Expertise with >15 year experience in peptide\/polymer chemistry \u2022 Ability to develop and manufacture, peptide solid support resins and chromatography stationary phases \u2022 Enhanced manufacturing competitiveness and Reliability \u2022 Rapid expansion in GLP-1 and non-GLP-1 peptide drugs Enhance Supply chain security and Peptides manufacturing competitiveness Montreal, Canada Hyderabad, India Investments aligns with Laurus strategy to strengthen Integrated scientific capabilities & manufacturing infrastructure \u00a9 2026 Laurus Labs Ltd. 29\/10\/2026Q2 & H1 - FY27 Results Presentation 7 Laurus Peptide CDMO platform and focus on continued capacity expansion Advancing end-to-end Peptide capabilities \u2013 Resins, amino acid derivatives, SPPS\/LPPS\/Purification\/Isolation Solid Phase Peptide Synthesis (SPPS) Bio-Ligation Liquid Phase Peptide Synthesis (LPPS) Purification Isolation Commercial API suppliesClinical supplies (Phase I, II and III) Pre-Clinical Peptide Development & Manufacturing Technologies cGMP Pilot facility operational Large-scale peptide manufacturing block operational Peptide team with >250 Scientists FDA and EU inspected facilities SPPS production suite, Vizag Laurus Labs captures entire Value Chain \u2022 Linear, cyclic & modified peptides with >16,000 L of Total Reactor Volume with synthesizers up to 2000L \u2022 Significant capacity under further expansion \u2022 Several large scale manufacturing lines operational \u2022 In-house enzyme manufacturing \u2022 Multiple DAC systems up to 1200mm dia \u2022 Multiple Lyophilizers up to 45 sq. m area \u2022 Various types and capacities of Spray drying \u00a9 2026 Laurus Labs Ltd. 29\/10\/2026Q2 & H1 - FY27 Results Presentation ATR progress (FY21-27*) * Cumulative addition including CWIP, Land, ETP and plant maintenance till September 2026 FY22-27* CAPEX : \u20b95180+ Cr (16% of Revenue) Advancing Key CAPEX projects across portfolio and technologies \u2022 >85% of Growth CAPEX planned into diversified portfolio with high-growth projects in API, Formulations, Peptides, Fermentation, Gene Therapy and ADCs \u2022 Healthy order book, strong internal pipeline, and key customer commitments \u2022 H1 CAPEX at \u20b9 864 Cr; 20% of Revenue \u2022 ATR improving in medium-term in-line with 6 year Long term average H1 CAPEX : \u20b9864 Cr (20% of Revenue) By Portfolio mix Medium term 6-Yr average 1.1x 8Laurus intends to invest > \u20b9 3,000 Cr over FY27 and FY28 across Manufacturing network and Capability expansion 1.4x 1.1x 1.1x 0.8x 0.8x 0.9x 1.0x FY21 FY25 FY26 1H FY27 87% 84% 16% Growth CAPEX API\/CDMO FDF 92% 8% API\/CDMO FDF \u00a9 2026 Laurus Labs Ltd. 29\/10\/2026Q2 & H1 - FY27 Results Presentation Enzyme Fermentation plant boosting biocatalysis capacity \u2022 Commercial scale manufacturing and Future expansion scope (>1.2mn liters) \u2022 Precision fermentation and strain engineering Large-scale API facility Unit -7 \u2022 Multiple API blocks, Flexible manufacturing \u2022 Large-scale API capacity \u2022 Future expansion 9 Commercial Gene & ADC platform with fill-finish \u2022 One-stop Service platform for complete ADC programs (Payload-linker, Conjugation, Fill-finish) \u2022 Commercial-scale capacity Large-scale Peptides API manufacturing \u2022 SPPS, LPPS and hybrid approaches + advanced downstream technology \u2022 Large scale capacity for GLP & non-GLP programs Key Growth investment projects \u2013 Enhancing broadest capability offering 1 2 3 4\"},{\"title\":\"Record Date\",\"summary\":\"Laurus Labs Limited has informed the Exchange that Record date for the purpose of Dividend  is 06-Nov-2026.\",\"source\":\"NSE\",\"published\":\"29-Oct-2026 15:14:07\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/LAURUSLABS_29102026151316_Dividend29102026.pdf\",\"disclosure_text\":\"October 29, 2026 To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai \u2013 400 001 Code: 540222 To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai \u2013 400 051 Code: LAURUSLABS Dear Sir \/ Madam, Sub: Approval for the payment of Interim Dividend for FY 2026-27 We would like to inform that the Board of Directors of the Company at their meeting held on October 29, 2026, has inter alia transacted and approved the payment of Interim Dividend of Re. 1.00\/- (i.e., 50%) per equity share of Rs.2\/- each, for the Financial Year 2026-27. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed \u201cNovember 6, 2026 \u201d as \u201cRecord Date \u201d for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after November 19, 2026. The Board Meeting commenced at 02.00 p.m. (IST) and concluded at 02.47 p.m. (IST). This is for your information and records. Thanking you. Yours sincerely, For Laurus Labs Limited V V Ravi Kumar Executive Director and CFO DIN: 01424180\"},{\"title\":\"General Updates\",\"summary\":\"appointment of Mr. Kundan Kumar Jha as Joint Company Secretary of the Company w.e.f. November 1, 2026\",\"source\":\"NSE\",\"published\":\"29-Oct-2026 15:10:51\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/LAURUSLABS_29102026151022_JointCS29102026.pdf\",\"disclosure_text\":\"October 29, 2026 To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai \u2013 400 001 Code: 540222 To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai \u2013 400 051 Code: LAURUSLABS Dear Sir \/ Madam, Sub: Approval for the appointment of Mr. Kundan Kumar Jha as Joint Company Secretary Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u201cSEBI Listing Regulations\u201d), we would like to inform that the Board of Directors of the Company at their meeting held on October 29, 2026, has inter alia based on the recommendation of the Nomination and Remuneration Committee and in line with the Company\u2019s succession planning process, approved the appointment of Mr. Kundan Kumar Jha (Associate Member of the Institute of Company Secretaries of India holding Membership No. A17612), as Joint Company Secretary, being a Key Managerial Personnel of the Company, with effect from November 1, 2026. The relevant details as required under the SEBI Listing Regulations read with SEBI Master Circular No. HO\/49\/14\/14(7)2025-CFD-POD2\/I\/3762\/2026 dated January 30, 2026, including a brief profile of Mr. Kundan Kumar Jha is annexed herewith as Annexure. The Board Meeting commenced at 02.00 p.m. (IST) and concluded at 02.47 p.m. (IST). This is for your information and records. Thanking you. Yours sincerely, For Laurus Labs Limited V V Ravi Kumar Executive Director and CFO DIN: 01424180 Encl: A\/a Annexure Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Pursuant to SEBI Master Circular no. HO\/49\/14\/14(7)2025-CFD-POD2\/I\/3762\/2026 dated January 30, 2026) Approval for the appointment of Mr. Kundan Kumar Jha, as Joint Company Secretary a Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise Appointment of Mr. Kundan Kumar Jha (Associate Member of the Institute of Company Secretaries of India holding Membership No. A17612) , as Joint Company Secretary , being a Key Managerial Personnel of the Company, in line with Company\u2019s succession planning process. b Date of appointment\/ re- appointment\/ cessation (as applicable) & term of appointment\/ re-appointment Appointment shall be effective from November 1, 2026 c Brief profile (in case of appointment) Mr. Kundan is a qualified Company Secretary and a member of the Institute of Company Secretaries of India (ICSI). He brings over 23 years of extensive experience in corporate governance, board processes, regulatory compliance, corporate law, listing regulations, and legal affairs. Before joining Laurus, he was associated with Cohance Lifesciences Limited as Company Secretary and Head of Legal. Earlier in his career, he held key positions at Dr. Reddy\u2019s Laboratories Limited, Rupa & Company Limited, Balrampur Chini Mills Limited, and Keventer Group. Throughout his professional journey, he has led numerous strategic projects, governance initiatives, and transformational changes across corporate secretarial, regulatory compliance, and legal functions, including board processes, mergers & acquisitions, under the Corporate Laws and the Listing Regulations of SEBI and SEC. d Disclosure of relationships between directors (in case of appointment of a director). Not applicable\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"source\":\"NSE\",\"published\":\"29-Oct-2026 14:55:53\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/LAURUSLABS_29102026145355_Outcome29102026.pdf\",\"disclosure_text\":\"October 29, 2026 To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai \u2013 400 001 Code: 540222 To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai \u2013 400 051 Code: LAURUSLABS Dear Sir \/ Madam, Sub: Outcome of the Board Meeting \u2013 October 29, 2026 We would like to inform that the Board of Directors of the Company at their meeting held on October 29, 2026, has inter alia transacted and approved the following businesses: (1) Approval of Unaudited Financial Results for the quarter and half-year ended September 30, 2026 Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u201c Listing Regulations \u201d), the Board of Directors approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2026, which are annexed herewith along with the Limited Review Reports issued by Deloitte Haskins & Sells LLP, the Statutory Auditors of the Company. The financial results will be available on the website of the Company at www.lauruslabs.com and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseinda.com, respectively. (2) Approval for the payment of Interim Dividend for FY 2026-27 The Board of Directors approved the payment of Interim Dividend of Re. 1.00\/ - (i.e., 50%) per equity share of Rs.2\/- each, for the Financial Year 2026-27. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed \u201cNovember 6, 2026\u201d as the \u201cRecord Date\u201d for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after November 19, 2026. (3) Approval for the appointment of Mr. Kundan Kumar Jha, as Joint Company Secretary The Board of Directors approved the appointment of Mr. Kundan Kumar Jha (Associate Member of the Institute of Company Secretaries of India holding Membership No. A17612) , as Joint Compa ny Secretary, being a Key Managerial Personnel of the Company, with effect from November 1, 2026, in line with the Company\u2019s succession planning process. The Board Meeting commenced at 02.00 p.m. (IST) and concluded at 02.47 p.m. (IST). This is for your information and records. Thanking you. Yours sincerely, For Laurus Labs Limited V V Ravi Kumar Executive Director and CFO DIN: 01424180 Encl: A\/a Sl. No. 1 2 3 4 5 6 7 8 (a) (b) 9 10 11 12 13 14 LAURUSLabs Chemistry for Better Living LAURUS LABS LIMITED (CIN: L24239AP2005PLC047518) Regd.Office: Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandai, Anakapalli District, Andhra Pradesh- 531021 Corp.Office: Plot No. 103, Road No.1, Jubilee Hills, Hyderabad 500033, Telangana, India. Tel: +91 040 6659 4333; Fax: +91 040 6659 4320; E-mail: secretarial@lauruslabs.com; Website : www.lauruslabs .com STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30,2026 Particulars Income (a) Revenue from operations (b) Other income Total income Expenses (a) Cost of materials consumed (b) Purchase of traded goods (c) Changes in inventories of finish ed goods, work-in\u00b7progress and stock-in-trade (d) Employee benefits expense (e) Other expenses (f) Depreciation and amortisation expense (g) Finance costs Total expenses Profit before tax (1-2) Tax expense (a) Current tax (b) Deferred tax Total Tax expense Net Profit after tax (3-4) Share of net profit\/ (loss) from associates and joint venture , net of tax Net Profit after taxes and share of net profiV(loss) from associales and joint venture (5+6) Other comprehensive incomef(loss) Items that will nol be reclassified subsequently to profit or loss: (i) Remeasurement gains\/ (losses) on defined benefit plans (ii) Income tax relating to items that will not be reclassified to profit or loss in subsequent periods (iii) Share in Other comprehensive income of associates and joint venture , net of tax Items that will be reclassified subsequently to profit or loss: Exchange differences on translating the financial statements of foreign operations Total other comprehensive incomef(loss), net of tax Total comprehensive income (7+8) Profit for the period attributable to: i) Equity hold ers of the company ii) Non-controlling interests Total comprehensive income for the period attributable to: i) Equity holders of the company ii) Non-controlling interests Paid-up equity share capital (face value~ 2\/- each) Other equity Earnings per equity share (face value~ '1\/- each) -Basic(~) - Diluted (~) See accompanymg notes to the fmanCJal results Registered Office Laurus Labs Limited Laurus Enclave, Plot Office 01. E. Bonangi Village. Parawada Mandai, Anakapalli District- 531021, Andhra Pradesh, India. T +91 891 682 1101. 1102, F +91 891 682 1103 E info@lauruslabs.com. W lauruslabs.com Quarter ended 30-Sep-26 30-Jun-26 (Unaudited) (Unaudited} 2,206.37 2,026.31 13.01 9.18 2,219.38 2,035.49 900.69 785.77 45.01 35.12 (129.61) (64.88) 265.71 258.70 374.27 373.33 127.39 123.87 44.10 42.22 1,627.56 1,554.13 591.82 481.36 16294 134.88 (7.86 (15.51 \\\\ 155.08 119.37 436.74 361.99 (0.551 0.08 436.19 36207 (2.42) (2.42) 0.61 0.61 (0.01) - t0.52J (0.40 (234) (221 433.85 359.86 441.48 367.60 (5.29) (5.53) 439.14 365.39 (5.29) (5.53) 108.06 108.05 8.17 6.81 8.16 6.80 (NCii1111U111\/15td) (Nfll41t11UU!Ii:>NJ Six montbs ended 3~Sep-25 30-Sep-26 30-Sep-25 (Unaudited) (Unaudited} (Unaudited} 1,653.47 4,232.68 3,223.04 26.96 22.19 37.39 1,680.43 4,254.87 3,.260.43 676.75 1,686.46 1,276.16 30.70 80.13 69.20 (44.01) (194.49) (44.57) 215.56 524.41 430.36 371.21 747.60 706.50 120.49 251.26 237.33 40.00 86.32 91.50 1,410.70 3,181.69 2,766.48 269.73 1,073.18 493.95 87.91 297.82 147.93 (11.93 (23.37) (8.81\\\\ 75.98 274.45 139.12 193.75 798.73 354.83 0.74 (0.47} 1.34 194.49 798.26 356.17 (0.26) (4.84) (0.51) 0.07 1.22 0.13 (0.01) (0.01) (0.01) [5.47) (0.92) (5.99 (5.67) (4.55) {6.38 188.82 793.71 349.79 194.97 809.08 357.99 (0.48) (10.82) (1.82) 189.30 804.53 351.61 (0.48) (10.82) (1.82) 107.96 108.06 107.96 3.61 14.98 6.63 3.61 14.96 6.63 (Nc>fii\/UUIIII L~J) (NQI1mnullli$c'd) (Not OMUifli:;N} Corporate Office Plot No. 103, Road No.1. Jubilee Hills, Hyderabad, Telangana - 500 033, India. T +91 40 6659 4333 F +91 40 6659 4320 ClN : L24239AP2005PLC047518 ?. ill Crores Year ended 31-Mar-26 (Audited) 6,812.90 54.95 6,867.85 2,794.34 17256 (271.44) 895.45 1,444.28 480.05 170.73 5,685.97 1,181.88 297.52 (5.49) 292.03 889.85 0.29 890.14 3.64 (0.91) 0.11 (8.74) (5.90 884.24 888.79 1.35 882.90 1.34 107.97 5,192.09 16.47 16.45 (\/lrll'llldll'ed) LAURUSLabs Sl. Particulars No. I ASSETS Non-current assets (a) Property, plant and equipment (b) Right-of-use assets (c) Capital work-in- progress (d) Goodwill (e) Other intangible assets (f) Financial assets (i) Investments (ii) Other financial assets (g) Deferred tax assets (net) (h) Income tax assets (net) (i) Other non<urrent assets Total non-current assets (1) Current assets (a) Inventories (b) Financial assets (i) Trade receivables (li) Cash and cash equivalents (iii) Bank balances other than Cash and cash equivalents (iv) Loans (v) Other financial assets (c) Other current assets Total current assets (2) Total - assets (1 +2) II EQUITY AND LIABILITIES Equity (a) Equity share capital (b) Other equity Total equity attributable to equity holders of Holding Company (c) Non<ontrolling interests Total equity (1) Non-current liabilities (a) Financial liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Provisions (c) Deferred tax liability (net) (d) Other non<urrent liabilities Total non-current liabilities (2) Current liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables -total outstanding dues of micro enterprises and small enterprises -total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Lease liabilities (iv) Other financial liabilities (b) Other current liabilities (c) Provisions (d) Income tax liabilities (net) Total current liabilities (3) Total- equity and liabilities (1 +2+3) -~sKINs X' rf l.q ~ t: CHARTERED r O ACCOUNTANTS ~ ..> \\\" ~0 t' Reg1stere Laurus Labs Limited Laurus Enclave, Plot Office 01. E. Bonangi Village, Parawada Mandai. Anakapalli District- 531021. Andhra Pradesh. India. T +91 891 682 1101, 1102, F +91 891 682 1103 E info@lauruslabs.com, W lauruslabs.com ( in Crores As at September 30, 2026 As at March 31, 2026 Unaudited Audited 3,846.55 3,873.23 241.30 232.71 1,282.44 773.28 246.30 246.30 17.20 18.40 310.02 309.27 46.38 44.26 19.74 - 4.54 244 315.64 182.09 6,330.11 5,681.98 2,659.06 2,342.16 2,241.53 2,155.04 24.45 112.66 4.29 1.04 0.95 0.93 4.63 3.21 248.66 214.17 5,183.57 4,829.21 11,513.68 10,511.19 108.06 107.97 5,952.51 5,192.09 6,060.57 5,300.06 120.48 131.30 6,181.05 5,431.36 553.32 611.34 127.59 111.49 25.24 20.63 145.01 132.09 26.23 29.38 501.15 539.47 1,378.54 1,444.40 1,936.56 1,786.15 4244 51.20 1,258.93 1,200.89 7.66 9.50 335.54 333.58 159.72 161.95 42.84 37.89 170.40 54.27 3,954.09 3,635.43 11,513.68 10,511-J.9.- ~\\\\..t:..Bs 9 .:::> ..,-\\\" ( ~ ~I 1:-\/ ()~ \u2022 Corporate Office '\\u002d\\u002d-::::=.. Plot No.103, Road No.1. Jubilee Hills. Hyderabad, Telangana - 500 033. India. T +91 40 6659 4333 F +91 40 6659 4320 CIN: L24239AP2005PLC047518 LAURUSLabs Chemistry for Better Living Consolidated Statement of Cash Flows Particulars Cash flow from operating activities Profit before tax Adjustments for : Depreciation and amortisation (Profit)\/Loss on sale of property, plant and equipment (net) Interest income Interest expenses Share based payment expense Net gain on foreign exchange fluctuations (unrealised) Allowance for expected credit loss and bad debts (net) Operating profit before working capital changes Movement In working capital: Increase in inventories (Increase)\/Decrease in trade receivables Increase in financial and non-financial assets Increase in trade payables Increase\/ (Decrease) in financial, non-financial liabilities and provisions Cash generated from operations Income tax paid Net cash generated from operating activities (A) Cash flow from investing activities Purchase of property, plant and equipment, including intangible assets, and movement in capital work in progress, capital advances and capital creditors Proceeds from sale of property, plant and equipment Movement in Bank balances other than Cash and cash equivalents Investment in associate Investment in others Interest received Net cash used in investing activities (B) Cash flow from financing activities Proceeds from exercise of employee stock options Repayment of long- term borrowings Proceeds from long - term borrowings Proceeds from\/ (Repayment of) short- term borrowings (net) Proceeds from\/ (Repayment of) supplier financing arrangements (net) Payment of lease liabilities Dividend paid Interest paid Proc eeds from Government Grant Net cash used in financing activities (C) Net decrease in cash and cash equivalents (A+B+C) Effect of exchange differ ences on cash and cash equivalents Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the period end Registered Office Laurus Labs Limited Laurus Enclave. Plot Office 01. E. Bonangi Village. Parawada Mandai. Anakapalli District- 531021. Andhra Pradesh. India. T +91 891 682 1101. 1102, F +91 891 682 1103 E info@lauruslabs.com. W lauruslabs .com ( in Crores For the six months ended For the six months ended September 30, 2026 September 30, 2025 Unaudited Unaudited 1,073.18 493.95 251.26 237.33 0.42 4.41 (4.60) (4.83) 81.98 88.66 5.47 5.41 (8.67) (19.26) 38.06 52.09 1,437.10 857.76 (316.91) (86.02) (151.21) 124.74 (26.34) (22.05) 64.16 59.14 (19.74) 253.81 987.06 1,187.38 (182.10) (94.25 804.96 1,093.13 (864.19) (488.91) 0.95 2.97 (3.25) 31.06 (1.23) (9.07) - (17.65) 4.60 4.83 _(863.12) {476.77) 15.29 18.95 (148.28) (178.18) 78.50 43.76 133.86 (396.73) 37.42 (15.53) (7.82) (6.41) (64.78) (43.14) (79.64) (90.68) 5.00 - (30.45) (667.% ) (88.61) (51.60) 0.40 1.83 112.66 99.54 24.45 49.77 Corporate Office Plot No. 103. Road No.1. ::Jubilee Hills. Hyderabad. Telangana - 500 033, India. T +91 40 6659 4333 F +91 40 6659 4320 CIN : L24239AP2005PLC047518 LAURUSLabs Chemistry for Better Living Notes: 1 The abov e consolidated unaudited financial results of Laurus Labs Limited (\\\"the Company') including its subsidiaries (Collectively known as \\\"the Group'), and its associat es and joint venture (as mentioned in note 3) has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 29, 2026. The statutory auditors of the Company have canied out a limited review on consolidated financial results and have issued an unmodifi ed conclusion in respect of the limited review for the quarter and six months ended September 30, 2026. 2 These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards ('lnd AS') prescribed under Section 133 of the Companies Act, 2013 (' the Act'') read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchang e Board of India (\\\"SEBI\\\"). 3 Th lid d f . I I . I d th f th f II e conso ate manc1a resu ts me u e e resu ts o e o owmg enhhes: Name of the Company Country of Nature of relationship %Holding Incorporation Sriam Labs Private Limited India Subsidiary 100% Laurus Holdings Limited UK Subsidiary 100% Lauru s Generics Inc USA Step-down subsidiary 100% Laurus Generics GmbH.i.L (Refer note 4c) Germany Step-down subsidiary 100% Laurus Synthesis Private Limited India Subsidiary 100% Lauru s Generics SA (Pty) Ltd South Africa Subsidiary 100% Laurus Bio Private Limited India Subsidia n \u00b7 78.34% Laurus Svecialty Chemicals Private Limited (Refer note 4al India Subsidia ry 100% lmmun oAdoptive Cell Thera py Private Limited India Associate 34.89% Ethan Enerl!Y India Private Lintited India Associate 26.00% KRKA Pharma Private Limited (Refer note 4b) India Joint Venture 49.00% . . 4 a) The Company mcorporated wholly owned subsidiary, Laurus Specmlty ChemiCals Privat e Lumted (LSCPL) m lndm on December 01, 2022. LSCPL has not comm enced its operations. b) Pursuant to the joint venture agreement enter ed into by the Company with KRKA Pharma Private Limited (\\\"KRKA\\\"), Capital contribution of~ 49 Crores have been made into KRKA in terms of the aforesaid agreement during the quarter ended December 31, 2025 for 49% stake. The Company has accounted for the investment in KRKA as joint venture. c) Durin g the quarter, Laurus Generics GmbH has filed for Liquidation. The liquidation process is ongoing and remains subject to completion of the statutory one-year credit or objection period ending August 2027. The Net assets and results of the subsidiary are not material to the group. 5 The Group is engaged in the manufacture and sale of ' Pharmaceuticals\\\" which constitut es a single reportable business segment as per lnd AS 108- 'Operating Segments' . 6 The Board of Directors of the Company, in its meeting held on August 21, 2025, approved the proposed Composite Scheme of Arrang ement (\\\"the Scheme ' ) for the d emerger of Identified Business Undertaking of Laurus Synth esis Private Limited into Sriam Labs Privat e Limited and amalgamation of Remaining Undertaking of Laurus Synthesis Privat e Lintited with the Company , subject to the necessary approval from National Company Law Tribunal, Amaravathi (\\\"NCLT\\\") und er section 230 and 232 of the Compani es Act, 2013 (\\\"the Act\\\") and other applicable provisions of the Act and the rules made thereund er. The Company have filed the Scheme with the Hon'ble National Company Law Tribunal , Ama ravati Bench at Amaravati, Andhra Pradesh , and accordingly the implementation of the Scheme is subject to the final approv als and sanctions of the applicabl e auth orities. Upon approval of the Scheme, Laurus Synth esis Private Limited shall stand dissolved without winding up with the Appointed Date of April 01, 2026 or such other date as the NCLT may approve. Pending such approv al, the consolidated financial results of the Company are presented without giving effect to the said merger. 7 During the six months ended September 30, 2026, the Company allotted 455,636 equity shares of~ 2\/- each, consequent to the exercise of the stock options by the employ ees of the Compan y under the Employee Stock Option Scheme. 8 The Board of Directors, at their meeting held on October 29, 2026 approved for the paym ent of interim dividend of< 1.00\/ - per equity share of~ 2\/ - each. Place: Hyderabad Date : October 29, 2026 Registered Office Laurus Labs Limited Laurus Enclave. Plot Office 01, E. Bonangi Village. Parawada Mandai. Anakapalli District- 531021. Andhra Pradesh, India. T +91 891 682 1101. 1102. F +91 891 682 1103 E info@lauruslabs.com, W lauruslabs.com By order of the Board For Laurus Labs Limited DJ{~~ Whole Time Director & Chief Executive Officer Corporate Office Plot No. 103, Road No.1. Jubilee Hills. Hyderabad. Telangana - 500 033. India. T +91 40 6659 4333 F +91 40 6659 4320 ClN : l24239AP2005PLC047518 Deloitte Chartered Accountants Meenakshi Pride Rock Tower Ill [Block- M], 8th & 9th floors Survey No. 23, Gachibowli Serilingampally Municipality Ranga Reddy Di_strict Hyderabad-500032 Haskins lr Sells LLP Telangana, India INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF LAURUS LABS LIMITED 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of LAURUS LABS LIMITED (\\\"the Parent\\\") and its subsidiaries (the Parent and its subsidiaries together referred to as \\\"the Group\\\"), and its share of the net loss after tax and total comprehensive loss of its associates and joint venture for the quarter and six months ended September 30, 2026 (\\\"the Statement\\\")\"}],\"recent_news\":[{\"summary\":\"Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"29-Oct-2026 14:55:53\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/LAURUSLABS_29102026145355_Outcome29102026.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"a press release dated October 29, 2026, titled \\\"Press Release on the Financial Results for the quarter and half-year ended September 30, 2026 along with the acquisition of Galenvs Sciences.\\\".\",\"category\":\"Press Release\",\"date\":\"29-Oct-2026 15:38:13\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/LAURUSLABS_29102026153754_1PressRelease29102026.pdf\",\"headline\":\"Investment \/ acquisition update\",\"impact\":\"The transaction can affect growth strategy, capital allocation or market access. Investors should consider the size of the investment, ownership acquired and expected returns.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"Laurus Labs Limited has informed the Exchange that Record date for the purpose of Dividend is 06-Nov-2026.\",\"category\":\"Record Date\",\"date\":\"29-Oct-2026 15:14:07\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/LAURUSLABS_29102026151316_Dividend29102026.pdf\",\"headline\":\"Shareholder-return \/ corporate action\",\"impact\":\"This affects shareholder returns or the share structure and can influence near-term investor interest.\",\"importance_score\":3,\"completeness_score\":4},{\"summary\":\"appointment of Mr. Kundan Kumar Jha as Joint Company Secretary of the Company effective. November 1, 2026.\",\"category\":\"General Updates\",\"date\":\"29-Oct-2026 15:10:51\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/LAURUSLABS_29102026151022_JointCS29102026.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":4}],\"insider_activity\":[{\"person\":\"PRATHIMA CHAVA\",\"category\":\"Insider \/ disclosed person\",\"type\":\"Pledge\",\"quantity\":\"200000\",\"post_holding\":\"433875\",\"date\":\"02-Dec-2024\",\"mode\":\"Pledge Creation\",\"source\":\"NSE PIT disclosure\"}],\"promoter_pledge\":{\"summary\":\"Recent NSE pledge\/encumbrance disclosures: PRATHIMA CHAVA: Pledge \u2014 200000 shares (02-Dec-2024)\",\"events\":[{\"person\":\"PRATHIMA CHAVA\",\"category\":\"Insider \/ disclosed person\",\"type\":\"Pledge\",\"quantity\":\"200000\",\"post_holding\":\"433875\",\"date\":\"02-Dec-2024\",\"mode\":\"Pledge Creation\",\"source\":\"NSE PIT disclosure\"}],\"source\":\"NSE PIT disclosure\"},\"shareholding_snapshot\":{\"promoter_pct\":27.47,\"public_pct\":72.53,\"fii_pct\":30.84,\"dii_pct\":11.86,\"mf_pct\":8.26,\"institutional_pct\":42.7,\"noninst_pct\":29.83,\"mf_scheme_count\":38,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"MIRAE ASSET NIFTY INDIA MANUFACTURING ETF\",\"shares\":21700881,\"pct\":4.02}],\"period\":\"30-SEP-2026\",\"submission_date\":\"21-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742798_21102026030442_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":27.47,\"previous_fii_pct\":28.0,\"previous_dii_pct\":13.74,\"previous_mf_pct\":10.15,\"previous_institutional_pct\":41.74,\"previous_mf_scheme_count\":38,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"bulk_block_deals\":[{\"deal_type\":\"Bulk\",\"date\":\"31 Aug, 2026\",\"party\":\"BNP PARIBAS FINANCIAL MARKETS\",\"side\":\"Sell\",\"quantity\":\"62,72,175\",\"price\":\"1,914.28\",\"value\":\"\u20b91,200.67 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Bulk\",\"date\":\"31 Aug, 2026\",\"party\":\"INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.\",\"side\":\"Sell\",\"quantity\":\"51,34,361\",\"price\":\"1,914.04\",\"value\":\"\u20b9982.74 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Bulk\",\"date\":\"31 Aug, 2026\",\"party\":\"SOCIETE GENERALE\",\"side\":\"Sell\",\"quantity\":\"28,10,437\",\"price\":\"1,903.84\",\"value\":\"\u20b9535.06 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Bulk\",\"date\":\"31 Aug, 2026\",\"party\":\"BNP PARIBAS FINANCIAL MARKETS\",\"side\":\"Buy\",\"quantity\":\"15,399\",\"price\":\"1,860.35\",\"value\":\"\u20b92.86 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Bulk\",\"date\":\"31 Aug, 2026\",\"party\":\"INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.\",\"side\":\"Buy\",\"quantity\":\"1,718\",\"price\":\"1,922.69\",\"value\":\"\u20b90.33 Cr\",\"source\":\"NSE-reported large-deal disclosure\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Laurus Labs share price rose 2.85% to \u20b92,244.00 today. See why LAURUSLABS is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":9647,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Laurus Labs Share Price Today: Why LAURUSLABS Is Rising 2.85% | 29 October 2026","_witty_meta_description":"Laurus Labs share price rose 2.85% to \u20b92,244.00 today. See why LAURUSLABS is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Laurus Labs share price today","_witty_reason_label":"Strong quarterly financial results and strategic CDMO acquisitions","_witty_reason_confidence":"high","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[225],"class_list":["post-9648","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-lauruslabs"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=9648"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9648\/revisions"}],"predecessor-version":[{"id":9649,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9648\/revisions\/9649"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/9647"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=9648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=9648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=9648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}